Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET.

Trial Profile

Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Zirconium-89 cetuximab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Pharmacokinetics
  • Acronyms COLO CETUX
  • Most Recent Events

    • 06 Jun 2017 Results (n=44) assessing predictive biomarkers to identify patients with primary resistant mCRC using patient data from NCT02117466 and NCT01691391trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 13 Jun 2013 Planned End Date changed from 17 Feb 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 28 May 2012 New source identified and integrated (Netherlands Trial Register, NTR3433).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top